Anti-tumor effect and immunomodulatory mechanism of atractylenolide Ⅱ on colon cancer mice

Abstract

Abstract:

ObjectiveTo explore the anti-tumor effect of atractylenolide Ⅱ （ATL-Ⅱ） on colon cancer and its immunomodulatory mechanism.MethodsA subcutaneous xenograft model of colon cancer was constructed using C57BL/6 mice. The mice were randomly divided into the model group （intraperitoneal injection of PBS）， ATL-Ⅱ low-dose （20 mg/kg） group， medium-dose （40 mg/kg） group， high-dose （60 mg/kg） group， as well as the 5-fluorouracil （5-FU 30 mg/kg） group， with 5 mice in each group， and the administration lasted for 21 days. HE staining was performed to detect the histopathological changes in the tumor tissues. The levels of expressions of Ki-67， Caspase-3， and Bcl-2 were detected by immunohistochemistry. The rates of CD8⁺T and NK1.1 positive cells in tumor tissues were detected by immunofluorescence. The serum levels of granzyme B （GzmB） and interferon-λ （IFN-λ） were measured by ELISA. The levels of expressions of PD-L1 and proteins involved in the ERK/MAPK signaling pathway were analyzed by Western blotting.ResultsThe tumor volumes of colon cancer xenograft mice in the model group， ATL -Ⅱ low-， medium-， high-dose groups and the 5-FU group were （1 845.17±65.72），（1 637.20±122.65），（1 232.86±209.16），（1 002.29±41.84）， and （911.59±294.71） mm³， respectively， with a statistically significant difference （F=125.61，P<0.001）. Compared with the model group， there were statistically significant differences in the ATL-Ⅱ low-， medium-， high-dose groups and the 5-FU group （allP<0.05）. Compared with the low-dose group， there were statistically significant differences in the ATL-Ⅱ medium-， high-dose groups and the 5-FU group （allP<0.05）， with a statistically significant difference also observed between the medium- and high-dose groups （P<0.05）. Compared with the ATL-Ⅱ medium- and high-dose groups， the 5-FU group demonstrated statistically significant differences （bothP<0.05）. The mass of tumors of the five groups was （1.34±0.11），（1.26±0.09），（0.93±0.07），（0.94±0.10）， and （0.59±0.08） g， respectively， with a statistically significant difference （F=88.88，P<0.001）. Compared with the model group， there were statistically significant differences in the ATL-Ⅱ medium-， high-dose groups and the 5-FU group （allP<0.05）. Compared with the low-dose group， there were statistically significant differences in the ATL-Ⅱ medium-， high-dose groups and the 5-FU group （allP<0.05）. Compared with the ATL-Ⅱ medium- and high-dose groups， there were statistically significant differences in the 5-FU group （bothP<0.05）. The spleen indexes of the five groups were 7.42±0.88， 7.38±1.32， 8.42±0.78， 9.72±1.18， and 6.16±1.05， respectively， with a statistically significant difference （F=33.20，P<0.001）. Compared with the model group， there were statistically significant differences in the ATL-Ⅱ medium- and high-dose groups and the 5-FU group （allP<0.05）. Compared with the low-dose group， there were statistically significant differences in the ATL-Ⅱ medium-， high-dose groups and the 5-FU group （allP<0.05）， and the spleen index in the high-dose group was higher than that in the medium-dose group （P<0.05）. Compared with the ATL-Ⅱ medium- and high-dose groups， there were statistically significant differences in the 5-FU group （bothP<0.05）. HE staining showed that， the tumor tissues of mice in the model group exhibited typical malignant tumor characteristics， including cellular density， large deeply stained nuclei， atypia， and reduced intercellular matrix. In tumor tissues of mice treated with ATL-Ⅱ and 5-FU， significantly reduced cell proliferation activity， loosely arranged cells， reduced mitotic activity， and markedly reduced necrotic areas were observed. In the ATL-Ⅱ medium-， high-dose groups and the 5-FU group， relatively small round or oval cells with large nuclei and deeply stained chromatin were observed. There were statistically significant differences in the percentage of positive areas for Ki-67， Caspase-3， and Bcl-2 among the five groups （F=13.86，P=0.043；F=477.63，P<0.001；F=40.48，P<0.001）. Compared with the model group， there were statistically significant differences in the ATL-Ⅱ medium-， high-dose groups and the 5-FU group （allP<0.05）. Compared with the low-dose group， there were statistically significant differences in the ATL-Ⅱ high-dose groups and the 5-FU group （bothP<0.05）. Compared with the medium- and high-dose ATL-Ⅱ groups， there were statistically significant differences in the proportion of Caspase-3 positive areas in the 5-FU group （bothP<0.05）. There was a statistically significant difference between the medium- and high-dose groups （P<0.05）. The positive cell rates for CD8⁺ T cells in the tumor tissues of the five groups were （10.33±3.53）%，（15.00±5.65）%，（30.33±10.51）%，（59.33±9.04）%， and （33.62±9.11）%， respectively， with a statistically significant difference （F=96.33，P<0.001）. Compared with the model group， there were statistically significant differences in the ATL-Ⅱ low-， medium-， high-dose groups and the 5-FU group （allP<0.05）. The ATL-Ⅱ medium-， high-dose groups and the 5-FU group were significantly different from the low-dose group （allP<0.05）， and a statistically significant difference was found between the medium- and high-dose groups （P<0.05）. The 5-FU group was significantly different from the ATL-Ⅱ high-dose group （P<0.05）. The positive cell rates for NK1.1 cells in the tumor tissues of the five groups were （12.33±6.52）%，（13.00±7.00）%，（35.33±9.51）%，（43.67±12.21）%， and （14.50±7.05）%， respectively， with a statistically significant difference （F=283.17，P<0.001）. The ATL-Ⅱ medium-， high-dose ATL-II groups and the 5-FU group showed statistically significant differences compared to the model group （allP<0.05）. The ATL-Ⅱ high-dose group was significantly different from the low-dose group （P<0.05）. The 5-FU group was significantly different from the ATL-Ⅱ medium- and high-dose groups （bothP<0.05）. The serum GzmB levels in the five groups were （5.00±1.00），（5.27±0.76），（8.27±0.61），（10.00±1.21），（6.15±0.69） ng/L， respectively， with a statistically significant difference （F=21.45，P<0.001）. The ATL-Ⅱ medium-， high-dose groups and the 5-FU group showed statistically significant differences compared to the model group （allP<0.05）. The ATL-Ⅱ medium- and high-dose groups were significantly different from the low-dose group （bothP<0.05）， and a statistically significant difference was found between the medium- and high-dose groups （P<0.05）. The 5-FU group were significantly differences from the ATL-Ⅱ medium- and high-dose groups （bothP<0.05）. The serum IFN-λ levels in the five groups were （617.33±65.06），（743.33±40.41），（910.00±36.06），（1 009.00±35.54），（703.62±56.00） ng/L， respectively， with a statistically significant difference （F=43.08，P<0.001）. The ATL-Ⅱ low-， medium-， and high-dose groups showed statistically significant differences compared to the model group （allP<0.05）. The ATL-Ⅱ medium- and high-dose groups were significantly differences from the low-dose group （bothP<0.05）， and a statistically significant difference was found between the medium- and high-dose groups （P<0.05）. The 5-FU group was significantly different from the ATL-Ⅱ medium- and high-dose groups （bothP<0.05）. There were statistically significant differences in the expression levels of PD-L1， p-ERK/ERK， and p-MEK/MEK proteins among the five groups of tumor tissues （F=125.34，P<0.001；F=89.63，P<0.001；F=35.33，P=0.002）. Statistically significant differences in PD-L1 expression levels were found among the low-， medium-， high-dose ATL-Ⅱ groups and the 5-FU group compared to the model group （allP<0.05）. The ATL-Ⅱ high-dose group and the 5-FU group showed statistically significant differences compared to the low-dose group （bothP<0.05）. A statistically significant difference was found between the ATL-Ⅱ medium- and high-dose groups （P<0.05）. The ATL-Ⅱ medium-dose group was significantly different from the 5-FU group （P<0.05）. Statistically significant differences in p-ERK/ERK expression levels were observed among the ATL-Ⅱ low-， medium-， high-dose groups and the 5-FU group compared to the model group （allP<0.05）. The ATL-Ⅱ medium-， high-dose groups and the 5-FU group showed statistically significant differences compared to the low-dose group （allP<0.05）. The 5-FU group was significantly different from the ATL-Ⅱ medium- and high-dose groups （bothP<0.05）. Statistically significant differences in p-MEK/MEK expression levels were found among the ATL-Ⅱ low-， medium-， high-dose groups and the 5-FU group compared to the model group （allP<0.05）. The 5-FU group was significantly different from the low-dose group （P<0.05）.ConclusionsAtractylenolide Ⅱ inhibits the activity of the ERK/MAPK signaling pathway， reduces the expression of PD-L1， enhances the infiltration of CD8⁺T cells and NK cells， and promotes tumor cell apoptosis， thereby it can exert an anti-cancer effect on colon cancer.

Key words:Colonic neoplasms,Atractylenolide Ⅱ,Neoplasm invasiveness,Apoptosis,B7-H1 antigen

Wang Mengju, Wang Xia. Anti-tumor effect and immunomodulatory mechanism of atractylenolide Ⅱ on colon cancer mice[J]. Journal of International Oncology, 2025, 52(9): 545-553.

Figures/Tables8

组别	体质量（g）	肿瘤体积（mm³）	肿瘤质量（g）	脾脏指数
模型组	20.54±1.07	1 845.17±65.72	1.34±0.11	7.42±0.88
ATL-Ⅱ低剂量组	20.08±0.88	1 637.20±122.65^a	1.26±0.09	7.38±1.32
ATL-Ⅱ中剂量组	20.12±1.63	1 232.86±209.16^ab	0.93±0.07^ab	8.42±0.78^ab
ATL-Ⅱ高剂量组	20.46±1.87	1 002.29±41.84^abc	0.94±0.10^ab	9.72±1.18^abc
5-FU组	19.00±1.60	911.59±294.71^abcd	0.59±0.08^abcd	6.16±1.05^abcd
F值	1.96	125.61	88.88	33.20
P值	0.451	<0.001	<0.001	<0.001

组别	Ki-67	Caspase-3	Bcl-2
模型组	32.33±9.50	6.67±1.53	93.00±6.56
ATL-Ⅱ低剂量组	24.33±5.69	11.00±2.65	94.00±12.12
ATL-Ⅱ中剂量组	19.33±2.52^a	16.33±3.06^a	51.67±5.51^ab
ATL-Ⅱ高剂量组	18.67±4.73^ab	52.33±4.04^abc	47.67±4.51^ab
5-FU组	16.33±2.52^ab	65.67±3.51^abcd	40.33±3.21^ab
F值	13.86	477.63	40.48
P值	0.043	<0.001	<0.001

组别	GzmB	IFN-λ
模型组	5.00±1.00	617.33±65.06
ATL-Ⅱ低剂量组	5.27±0.76	743.33±40.41^a
ATL-Ⅱ中剂量组	8.27±0.61^ab	910.00±36.06^ab
ATL-Ⅱ高剂量组	10.00±1.21^abc	1 009.00±35.54^abc
5-FU组	6.15±0.69^acd	703.62±56.00^cd
F值	21.45	43.08
P值	<0.001	<0.001

组别	PD-L1	p-ERK/ERK	p-MEK/MEK
模型组	1.58±0.25	1.33±0.20	1.04±0.39
ATL-Ⅱ低剂量组	0.88±0.24^a	0.61±0.21^a	0.74±0.24^a
ATL-Ⅱ中剂量组	0.91±0.18^a	0.44±0.29^ab	0.70±0.20^a
ATL-Ⅱ高剂量组	0.62±0.11^abc	0.57±0.15^ab	0.71±0.17^a
5-FU组	0.54±0.17^abc	0.23±0.11^abcd	0.63±0.19^ab
F值	125.34	89.63	35.33
P值	<0.001	<0.001	0.002

References19

[1]	Abedizadeh R, Majidi F, Khorasani HR, et al. Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments[J].Cancer Metastasis Rev,2024,43(2): 729-753. DOI:10.1007/s10555-023-10158-3.
[2]	Fan A, Wang B, Wang X, et al. Immunotherapy in colorectal cancer: current achievements and future perspective[J].Int J Biol Sci,2021,17(14): 3837-3849. DOI:10.7150/ijbs.64077. pmid:34671202
[3]	Lin Y, Chen K, Zhu M, et al. Atractylenolide Ⅱ regulates the proli-feration, ferroptosis, and immune escape of hepatocellular carcinoma cells by inactivating the TRAF6/NF-κB pathway[J].Naunyn Schmiedebergs Arch Pharmacol,2024,397(10): 7697-7710. DOI:10.1007/s00210-024-03046-2.
[4]	Tian S, Ren L, Liu C, et al. Atractylenolide Ⅱ suppresses glycolysis and induces apoptosis by blocking the PADI3-ERK signaling pathway in endometrial cancer cells[J].Molecules,2024,29(5): 939. DOI:10.3390/molecules29050939.
[5]	Zhang Y, Liu Y, Wang J, et al. Atractylenolide Ⅱ inhibits tumor-associated macrophages (TAMs)-induced lung cancer cell metastasis[J].Immunopharmacol Immunotoxicol,2022,44(2): 227-237. DOI:10.1080/08923973.2022.2037629.
[6]	Lei X, Lei Y, Li JK, et al. Immune cells within the tumor micro-environment: biological functions and roles in cancer immunotherapy[J].Cancer Lett,2020,470: 126-133. DOI:10.1016/j.canlet.2019.11.009. pmid:31730903
[7]	Zhang R, Wang Z, Yu Q, et al. Atractylenolide Ⅱ reverses the influence of lncRNA XIST/miR-30a-5p/ROR1 axis on chemo-resistance of colorectal cancer cells[J].J Cell Mol Med,2019,23(5): 3151-3165. DOI:10.1111/jcmm.14148.
[8]	Xie Z, Lin M, He X, et al. Chemical constitution, pharmacological effects and the underlying mechanism of atractylenolides: a review[J].Molecules,2023,28(10): 3987. DOI:10.3390/molecules28103987.
[9]	Wu Y, Dai S, Zhang Y, et al. Atractylenolide Ⅱcombined with interferon-γ synergistically ameliorates colorectal cancer progression in vivo and in vitro by blocking the NF-κB p65/PD-L1 pathway[J].J Cancer,2024,15(13): 4328-4344. DOI:10.7150/jca.96647.
[10]	Sahoo G, Samal D, Khandayataray P, et al. A review on caspases: key regulators of biological activities and apoptosis[J].Mol Neurobiol,2023,60(10): 5805-5837. DOI:10.1007/s12035-023-03433-5. pmid:37349620
[11]	Wang J, Nasser MI, Adlat S, et al. Atractylenolide Ⅱ induces apoptosis of prostate cancer cells through regulation of AR and JAK2/STAT3 signaling pathways[J].Molecules,2018,23(12): 3298. DOI:10.3390/molecules23123298.
[12]	Shang S, Yang YW, Chen F, et al. TRIB3 reduces CD8⁺T cell infiltration and induces immune evasion by repressing the STAT1-CXCL10 axis in colorectal cancer[J].Sci Transl Med,2022,14(626): eabf0992. DOI:10.1126/scitranslmed.abf0992.
[13]	Basu R, Whitlock BM, Husson J, et al. Cytotoxic T cells use mechanical force to potentiate target cell killing[J].Cell,2016,165(1): 100-110. DOI:10.1016/j.cell.2016.01.021. pmid:26924577
[14]	Remsik J, Tong X, Kunes RZ, et al. Interferon-γ orchestrates leptomeningeal anti-tumour response[J].Nature,2025,643(8073): 1087-1096. DOI:10.1038/s41586-025-09012-z.
[15]	Zhou Y, Cheng L, Liu L, et al. NK cells are never alone: crosstalk and communication in tumour microenvironments[J].Mol Cancer,2023,22(1): 34. DOI:10.1186/s12943-023-01737-7.
[16]	Huntington ND, Cursons J, Rautela J. The cancer-natural killer cell immunity cycle[J].Nat Rev Cancer,2020,20(8): 437-454. DOI:10.1038/s41568-020-0272-z. pmid:32581320
[17]	Zheng Z, Wieder T, Mauerer B, et al. T cells in colorectal cancer: unravelling the function of different T cell subsets in the tumor microenvironment[J].Int J Mol Sci,2023,24(14): 11673. DOI:10.3390/ijms241411673.
[18]	Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer[J].Lancet Oncol,2005,6(5): 322-327. DOI:10.1016/S1470-2045(05)70168-6. pmid:15863380
[19]	Wang L, Wang J, Wang N, et al. ANLN promotes head and neck squamous cell carcinoma progression by upregulating PD-L1 via the ERK-MAPK pathway[J].iScience,2025,28(2): 111633. DOI:10.1016/j.isci.2024.111633.